NCT04908280

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Exploratory Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

Conditions

• Discoid Lupus Erythematosus

Interventions

Type	Name	Description
DRUG	Ruxolitinib	1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.

Timeline

• Start date: 2022-05-04
• Primary completion: 2024-03-04
• Completion: 2024-03-04
• First posted: 2021-06-01
• Last updated: 2025-05-20
• Results posted: 2025-05-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study